Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Strata Critical Medical (SRTA) over the last 7 years, with Q3 2025 value amounting to -$5.2 million.

  • Strata Critical Medical's Gains from Investment Securities fell 183745.82% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 132940.14%. This contributed to the annual value of $5.7 million for FY2024, which is 36743.53% up from last year.
  • Per Strata Critical Medical's latest filing, its Gains from Investment Securities stood at -$5.2 million for Q3 2025, which was down 183745.82% from -$77000.0 recorded in Q2 2025.
  • Over the past 5 years, Strata Critical Medical's Gains from Investment Securities peaked at $14.9 million during Q2 2021, and registered a low of -$19.3 million during Q2 2022.
  • In the last 5 years, Strata Critical Medical's Gains from Investment Securities had a median value of -$77000.0 in 2025 and averaged -$751842.1.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 334594.59% in 2022, then surged by 36813.9% in 2024.
  • Quarter analysis of 5 years shows Strata Critical Medical's Gains from Investment Securities stood at -$10.9 million in 2021, then soared by 81.81% to -$2.0 million in 2022, then soared by 185.58% to $1.7 million in 2023, then soared by 368.14% to $7.9 million in 2024, then plummeted by 165.35% to -$5.2 million in 2025.
  • Its Gains from Investment Securities was -$5.2 million in Q3 2025, compared to -$77000.0 in Q2 2025 and $4.3 million in Q1 2025.